DOCSLIB.ORG
  • Sign Up
  • Log In
  • Upload
  • Sign Up
  • Log In
  • Upload
  • Home
  • »  Tags
  • »  Perhexiline

Perhexiline

  • PROZAC Product Monograph Page 1 of 49 Table of Contents

    PROZAC Product Monograph Page 1 of 49 Table of Contents

  • The Myocardial Metabolic and Haemodynamic Effects of Perhexiline in I]Y Wvo and Nv Vitro Models

    The Myocardial Metabolic and Haemodynamic Effects of Perhexiline in I]Y Wvo and Nv Vitro Models

  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    2D6 Substrates 2D6 Inhibitors 2D6 Inducers

  • Drug-Induced Fatty Liver Disease

    Drug-Induced Fatty Liver Disease

  • Drug-Induced Inhibition of Mitochondrial Fatty Acid Oxidation

    Drug-Induced Inhibition of Mitochondrial Fatty Acid Oxidation

  • Abnormal Laboratory Results Therapeutic Drug Monitoring

    Abnormal Laboratory Results Therapeutic Drug Monitoring

  • DOMASYS Standard

    DOMASYS Standard

  • Repositioning Fda-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome

    Repositioning Fda-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome

  • Inhibition of Mitochondrial Fatty Acid Oxidation in Drug-Induced Hepatic Steatosis*

    Inhibition of Mitochondrial Fatty Acid Oxidation in Drug-Induced Hepatic Steatosis*

  • Perhexiline Maleate in the Treatment of Fibrodysplasia Ossificans Progressiva

    Perhexiline Maleate in the Treatment of Fibrodysplasia Ossificans Progressiva

  • Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation, Final, July 2009

    Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation, Final, July 2009

  • Supplemental Material BMJ Open Doi: 10.1136/Bmjopen-2020-039104 :E039104. 10 2020; BMJ Open , Et Al. Randall SM

    Supplemental Material BMJ Open Doi: 10.1136/Bmjopen-2020-039104 :E039104. 10 2020; BMJ Open , Et Al. Randall SM

  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

    Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1

  • Pharmaceuticals As Environmental Contaminants

    Pharmaceuticals As Environmental Contaminants

  • The Effect of Weight on Plasma Perhexiline Disposition Is

    The Effect of Weight on Plasma Perhexiline Disposition Is

  • Queensland Health List of Approved Medicines

    Queensland Health List of Approved Medicines

  • Cardiovascular Calcium Channel Blockers: Historical Overview

    Cardiovascular Calcium Channel Blockers: Historical Overview

  • OUH Formulary Approved for Use in Breast Surgery

    OUH Formulary Approved for Use in Breast Surgery

Top View
  • A Computational Tool for Pathway-Based Rational Drug Repositioning Supplementary Information
  • Medicines for Cardiovascular Health
  • The Natural History of Histologically Proved Drug Induced Liver Disease Gut: First Published As 10.1136/Gut.44.5.731 on 1 May 1999
  • Cytochrome P450 Drug Interaction Table
  • Investigation Into in Vitro Anti-Leishmanial Combinations of Calcium Channel Blockers and Current Anti-Leishmanial Drugs
  • Impaired Oxidation of Debrisoquine in Patients with Perhexiline Liver Injury
  • New Zealand Data Sheet
  • GLEEVEC) in Patients with HIV Related Kaposi's Sarcoma
  • Customised in Vitro Model to Detect Human Metabolism-Dependent
  • Florencio Zaragoza Dörwald Lead Optimization for Medicinal Chemists
  • ICCB-L Plate (10 Mm / 3.33 Mm) ICCB-L Well Vendor ID Chemical Name
  • TG Gates: a Large-Scale Transcriptomics and Pathology Database Florian Caiment
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
  • Of 33 Appendix
  • Polymorphic Hydroxylation of Perhexilinemaleate
  • Title a Phase 2, Multi-Center, Open-Label, Ascending Dose Study
  • Drug Consumption Databases in Europe
  • In Vitro to in Vivo Extrapolation for Drug-Induced Liver Injury Using a Pair Ranking Method


© 2024 Docslib.org    Feedback